Position on Key Issues
In our focus to help patients with serious diseases, we have developed clear positions on important policies and topics related to healthcare, regulatory, intellectual property and pricing. Learn more about our positions below.
Clinical Trial Communication Commitment
We believe that making clinical trial information available to patients, investigators, researchers and physicians is a critical part of our commitment to transparency, scientific exchange and, ultimately, innovation.
Counterfeit drugs and product tampering, theft or diversion represent a threat to providing our customers with the safest, most effective and highest quality products. While there is no single solution to this issue, we have efforts in place to help ensure the integrity of our products within the supply chain and further patient safety.
Early Patient Access to Investigational Medicines
We welcome requests for early patient access from physicians treating patients who face a serious or life-threatening illness and have no further treatment options or a clinical trial available to them. Our goal is to ensure that appropriate patients can obtain access to our investigational medicines.
PhRMA's Code on Interactions with Health Care Professionals
We are committed to following the highest ethical standards and all legal requirements in our promotion of drugs to health care professionals. Our drug promotion is guided by our company’s mission and commitment and guidelines such as the Code on Interactions with Health Care Professionals developed by the Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA's Guiding Principles on Direct-to-Consumer Advertisements
We have a long-standing commitment to responsible and effective consumer communications. We believe responsible direct-to-consumer (DTC) advertising can foster informed conversations between patients and their health care professionals. We have adopted DTC advertising guidelines developed by the Pharmaceutical Research and Manufacturers of America (PhRMA).